eloralintide
Sponsor ELI Lilly & CO · listed as LLY
eloralintide is a drug asset sponsored by ELI Lilly & CO, listed as LLY. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Jan 2028 (month precision, medium confidence), tied to trial NCT07282600. That trial is in Phase 3 and currently recruiting, studying Overweight. It appears across 5 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for eloralintide in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT07282600 catalyst | Phase 3 | Recruiting | 2028-01 | Experimental | Eli Lilly and Company | Overweight; Obesity |
| NCT07321886 | Phase 3 | Recruiting | 2028-03 | Experimental | Eli Lilly and Company | Obesity; Overweight |
| NCT07353931 | Phase 3 | Recruiting | 2028-03 | Experimental | Eli Lilly and Company | Osteoarthritis; Overweight or Obesity |
| NCT07369011 | Phase 3 | Recruiting | 2028-03 | Experimental | Eli Lilly and Company | Sleep Apnea, Obstructive; Obesity; Overweight |
| NCT07392190 | Phase 3 | Recruiting | 2028-06 | Experimental | Eli Lilly and Company | Overweight; Obesity |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More LLY catalysts